Abstract:Background & Aims Hepatitis E virus (HEV) is a globally prevalent pathogen, annually resulting in 20 million infections, 3 million cases of clinical disease, and 60,000 fatalities worldwide, significantly endangering pregnant women and immunocompromised individuals. HEV-related research has been considerably delayed, and no HEV-specific therapeutics have yet been developed. We aimed to discover efficient anti-HEV drugs through high throughput screening that could be validated in vitro and in a preclinical animal study in vivo, and elucidate the underlying antiviral mechanism. Methods Using appropriate cellular and rodent HEV infection models, we studied a critical pathway for host-HEV interaction and performed a preclinical study of the corresponding antivirals by targeting proteostasis of the HEV replicase. Results We found 17 inhibitors that target HEV-HSP90 interactions by an unbiased compound library screening on human hepatocytes harboring an HEV replicon. Inhibitors of HSP90 (iHSP90) markedly suppressed HEV replication with efficacy exceeding that of conventional antivirals (IFNα and ribavirin) in vitro. Mechanistically, iHSP90 treatment released the viral replicase ORF1 protein from the ORF1-HSP90 complex and triggered ORF1 for rapid ubiquitin/proteasome-mediated degradation, resulting in abrogated HEV replication. Furthermore, a preclinical trial in a Mongolian gerbil HEV infection model showed this novel anti-HEV strategy to be safe, efficient, and able to prevent HEV-induced liver damage. Conclusions This study collectively illustrates a critical proteostasis pathway for host-HEV interaction and paves the way for translating the new understanding of the HEV life cycle into clinically promising antivirals. Impact and implications Appropriate treatment options for HEV-infected pregnant women as well as immunocompromised patients are lacking, creating an urgent need for developing safe HEV-specific therapies. This study identified new antivirals (inhibitors of HSP90) that significantly decrease the HEV infection by targeting viral replicase for degradation. Moreover, these anti-HEV drugs were validated in an HEV rodent model and found to be safe and efficient for prevention of HEV-induced liver injury in preclinical experiments. Our findings substantially promote the understanding of HEV pathobiology and the pace of antiviral development.

Mitochondrial dysfunction and mitophagy pathway activation in hepatitis E virus-infected livers of Mongolian gerbils

Hepatitis E Virus Induces Hepatocyte Apoptosis Via Mitochondrial Pathway in Mongolian Gerbils

Antigen detection and apoptosis in Mongolian gerbil’s kidney experimentally intraperitoneally infected by swine hepatitis E virus

Molecular and Structural Changes Related to Hepatitis E Virus Antigen and Its Expression in Testis Inducing Apoptosis in Mongolian Gerbil Model.

Distribution of Mongolian Gerbil Hepatitis Viruses and Histopathology in the Digestive System of Mongolian Gerbils

Hepatitis E Virus Induces Brain Injury Probably Associated with Mitochondrial Apoptosis

Increased Mast Cell Activation in Mongolian Gerbils Infected by Hepatitis E Virus

An Immunocompetent Mongolian Gerbil Model for Hepatitis E Virus Genotype 1 Infection

Effect of Swine Hepatitis E Virus on the Livers of Experimentally Infected Mongolian Gerbils by Swine Hepatitis E Virus.

Distinct disease features of acute and persistent genotype 3 hepatitis E virus infection in immunocompetent and immunosuppressed Mongolian gerbils

Experimental Infection of Mongolian Gerbils by A Genotype 4 Strain of Swine Hepatitis E Virus

Animal Models of Hepatitis E Infection: Advances and Challenges.

Mongolia Gerbils Are Broadly Susceptible to Hepatitis E Virus

NLRP3 Inflammasome Activation Mediates Hepatitis E Virus-Induced Neuroinflammation

Strain- and Subtype-Specific Replication of Genotype 3 Hepatitis E Viruses in Mongolian Gerbils

Altered Faecal Microbiota on the Expression of Th Cells Responses in the Exacerbation of Patients with Hepatitis E Infection.

Gut microbiota dysbiosis associated with plasma levels of Interferon-gamma and viral load in patients with acute hepatitis E infection

Realm of hepatitis E: Challenges and opportunities.

Extrahepatic Manifestations Related to Hepatitis E Virus Infection and Their Triggering Mechanisms.

Targeting proteostasis of the HEV replicase to combat infection in preclinical models

Evidence of Hepatitis E virus breaking through the blood–brain barrier and replicating in the central nervous system